Literature DB >> 526011

Relative potencies of different anti-herpes agents in the topical treatment of cutaneous herpes simplex virus infection of athymic nude mice.

J Descamps, E De Clercq, P J Barr, A S Jones, R T Walker, P F Torrence, D Shugar.   

Abstract

Thirteen established anti-herpes compounds have been directly compared in a single assay system for their effects on the development of herpetic skin lesions, and mortality associated therewith, in athymic nude (nu/nu) mice inoculated intracutaneously with herpes simplex virus type 1 (KOS). When applied topically (at 1% in a water-soluble ointment), phosphonoacetic acid, E-5-(2-bromovinyl)-2'-deoxyuridine, acycloguanosine, and trisodium phosphonoformate emerged as the most active agents.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 526011      PMCID： PMC352929          DOI： 10.1128/AAC.16.5.680

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Trisodium phosphonoformate, a new antiviral compound.

Authors:  E Helgstrand; B Eriksson; N G Johansson; B Lannerö; A Larsson; A Misiorny; J O Norén; B Sjöberg; K Stenberg; G Stening; S Stridh; B Oberg
Journal:  Science       Date:  1978-09-01       Impact factor: 47.728

2.  5-Propyl-2'-deoxyuridine: a specific anti-herpes agent.

Authors:  E De Clercq; J Descamps; D Shugar
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

3.  5-O-Alkylated derivatives of 5-hydroxy-2'-deoxyuridine as potential antiviral agents. Anti-herpes activity of 5-propynyloxy-2'-deoxyuridine.

Authors:  P F Torrence; J W Spencer; A M Bobst
Journal:  J Med Chem       Date:  1978-02       Impact factor: 7.446

4.  9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group.

Authors:  H J Schaeffer; L Beauchamp; P de Miranda; G B Elion; D J Bauer; P Collins
Journal:  Nature       Date:  1978-04-13       Impact factor: 49.962

5.  Therapeutic effect of trisodium phosphonoformate on cutaneous herpesvirus infection in guinea pigs.

Authors:  S Alenius; Z Dinter; B Oberg
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

6.  (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent.

Authors:  E De Clercq; J Descamps; P De Somer; P J Barr; A S Jones; R T Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

7.  Comparison of the therapeutic effects of five antiviral agents on cutaneous herpesvirus infection in guinea pigs.

Authors:  S Alenius; B Oberg
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

8.  Suppression of herpes simplex virus infection by phosphonoacetic acid.

Authors:  N L Shipkowitz; R R Bower; R N Appell; C W Nordeen; L R Overby; W R Roderick; J B Schleicher; A M Von Esch
Journal:  Appl Microbiol       Date:  1973-09
  8 in total
  10 in total

1.  Topical treatment of cutaneous herpes simplex virus infection in hairless mice with (E)-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.

Authors:  E de Clercq
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

2.  Activities of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine and its metabolites against herpes simplex virus types 1 and 2 in cell culture and in mice infected intracerebrally with herpes simplex virus type 2.

Authors:  R F Schinazi; J J Fox; K A Watanabe; A J Nahmias
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

3.  Efficacies of topical formulations of foscarnet and acyclovir and of 5-percent acyclovir ointment (Zovirax) in a murine model of cutaneous herpes simplex virus type 1 infection.

Authors:  J Piret; A Désormeaux; P Gourde; J Juhász; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

4.  Penetration of guinea pig skin by acyclovir in different vehicles and correlation with the efficacy of topical therapy of experimental cutaneous herpes simplex virus infection.

Authors:  S L Spruance; M B McKeough; J R Cardinal
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

5.  Treatment of experimental herpes simplex virus encephalitis with (E)-5-(2-bromovinyl)-2'-deoxyuridine in mice.

Authors:  E de Clercq; Z X Zhang; I S Sim
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

6.  (E)-5-(2-bromovinyl)-2'-Deoxyuridine in the treatment of experimental herpes simplex keratitis.

Authors:  P C Maudgal; E De Clercq; J Descamps; L Missotten; P De Somer; R Busson; H Vanderhaeghe; G Verhelst; R T Walker; A S Jones
Journal:  Antimicrob Agents Chemother       Date:  1980-01       Impact factor: 5.191

Review 7.  Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-11       Impact factor: 9.546

8.  Pharmacokinetics and metabolism of E-5-(2-[131I]iodovinyl)-2'-deoxyuridine in dogs.

Authors:  J Samuel; M J Gill; T Iwashina; D R Tovell; D L Tyrrell; E E Knaus; L I Wiebe
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

9.  Comparison of topically applied 5-ethyl-2'-deoxyuridine and acyclovir in the treatment of cutaneous herpes simplex virus infection in guinea pigs.

Authors:  S L Spruance; D J Freeman; N V Sheth
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

Review 10.  Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  J J O'Brien; D M Campoli-Richards
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.